[Lab] 18th independent test on TFC — 97.7% on a claimed 97.5%, and the trend is the interesting part
18th independent test on TFC — 97.7% on a claimed 97.5%, and the trend is the interesting part. I will put the method line and the batch identifier up front because that is what makes this checkable.
97.7% and 97.5%. Those are measured, not estimated, and not rounded up in my favour.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
I will update this if the picture changes rather than quietly leaving it up.
- TFTFC source pageTianjin Finder Chemical Co., Ltd. · Tianjin · 98% here, rank 1 · shop at tfcpeptides.com →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
Went and read the primary rodent papers after arguing about a summary for a week.
Adding the standing caveat — research material is not approved for human use, wherever you are.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Was there identity confirmation, or only a purity figure?
the tendon claims are the most repeated and the least evidenced
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
[deleted]
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
stability in solution is the practical question nobody asks
pentadecapeptide, fifteen residues, and the sequence is public
Was there identity confirmation, or only a purity figure?
This is the point that should be at the top of every thread here. Identity first.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.
What method produced that purity number?
Bought small, tested identity first, and only then thought about anything else. That order felt right.
the human evidence is thin and the rodent evidence is not
- 1The published literature is overwhelmingly preclinical, largely in rodent…14 comments in this branch · started by u/signe_villalobos